News
TEVA ▼ -3.7% - Teva Pharmaceutical Industries Limited
TEVA ▼ -3.7% - Teva Pharmaceutical Industries Limited
$TEVA - Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
02-NOV-2026 08:00 AM ET
Share this post
More filings for $TEVA
TEVA ▲ +0.3% - Teva Pharmaceutical Industries LimitedNov 20, 2026TEVA ▼ -0.9% - Teva Pharmaceutical Industries LimitedNov 18, 2026TEVA - Teva Pharmaceutical Industries Limited - SEC Filing Update (16-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 16, 2026TEVA ▲ +0.4% - Teva Pharmaceutical Industries LimitedNov 16, 2026TEVA ▲ +1.3% - Teva Pharmaceutical Industries LimitedNov 11, 2026TEVA - Teva Pharmaceutical Industries Limited - SEC Filing Update (10-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 10, 2026
View full $TEVA filing history →💬 Comments
Loading comments…
Leave a comment
